Entergy Mississippi, Inc. 1M BD 66
- Market Cap (Standard market cap (price × shares outstanding) from the company profile — shown because the screener's float-computed cap is unavailable for this ticker.)
- $171.2M
- Price
- $19.80
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.05%
- Volume
- 5.0K
About
Entergy Mississippi, LLC generates, transmits, and distributes, and sells coal and solar power primarily to retail and wholesale customers in Mississippi. It also provides gas services to customers. Entergy Mississippi, LLC was formerly known as Entergy Mississippi Power and Light, LLC and changed its name to Entergy Mississippi, LLC on December 01, 2018. The company was incorporated in 2018 and is based in Jackson, Mississippi. Entergy Mississippi, LLC operates as a subsidiary of Entergy Utility Holding Company, LLC.
Quick stats
Quick-stats data pending — refreshes nightly.
Key info
SectorUtilities
IndustryRegulated Electric
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000066901
Websitewww.entergy-mississippi.com
AI Summary
AI-generated4mo agostandard
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced expanded Phase 2a results for EMP-01 (oral R-MDMA) in adults with Social Anxiety Disorder (SAD) (n=70), demonstrating clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes. At Day 43, EMP‑01 achieved a 38% reduction vs 15% on placebo (Hedges' g=0.84) on the patient-reported Social Phobia Inventory (SPIN), a 32% reduction vs 14% on placebo on the Subtle Avoidance Frequency Examination (SAFE), and a previously reported −11.9-point LS mean difference (LSMD) on the Liebowitz Social Anxiety Scale (LSAS) versus placebo (g=0.45), with 49% responder rates on both Clinical Global Impression-Improvement (CGI-I) (previously reported) and Patient Global Impressions of Change (PGI-C). EMP-01 was well tolerated, with no severe or serious adverse events.